ARCEDE Stock Overview
Arcede Pharma AB (publ) develops drug candidates to treat chronic obstructive pulmonary disease (COPD) and asthma.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Arcede Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.097 |
| 52 Week High | kr2.39 |
| 52 Week Low | kr0.05 |
| Beta | 0 |
| 1 Month Change | 14.35% |
| 3 Month Change | 21.50% |
| 1 Year Change | -95.56% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| ARCEDE | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -10.8% | -0.8% | -0.7% |
| 1Y | -95.6% | 55.7% | 4.4% |
Return vs Industry: ARCEDE underperformed the Swedish Pharmaceuticals industry which returned 60% over the past year.
Return vs Market: ARCEDE underperformed the Swedish Market which returned 10.3% over the past year.
Price Volatility
| ARCEDE volatility | |
|---|---|
| ARCEDE Average Weekly Movement | 19.2% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: ARCEDE's share price has been volatile over the past 3 months.
Volatility Over Time: ARCEDE's weekly volatility has decreased from 28% to 19% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | n/a | arcedepharma.com |
Arcede Pharma AB (publ) develops drug candidates to treat chronic obstructive pulmonary disease (COPD) and asthma. Its project portfolio includes RCD405 for the treatment of COPD and asthma. The company was incorporated in 2003 and is based in Lund, Sweden.
Arcede Pharma AB (publ) Fundamentals Summary
| ARCEDE fundamental statistics | |
|---|---|
| Market cap | kr568.26k |
| Earnings (TTM) | kr0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs ARCEDE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARCEDE income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr0 |
| Earnings | kr0 |
Last Reported Earnings
n/a
Next Earnings Date
May 16, 2024
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ARCEDE perform over the long term?
See historical performance and comparison